Atossa Genetics (ATOS) Reaches New 1-Year Low at $2.26

Atossa Genetics Inc (NASDAQ:ATOS) hit a new 52-week low on Thursday . The stock traded as low as $2.26 and last traded at $2.30, with a volume of 1100 shares changing hands. The stock had previously closed at $2.34.

Several equities research analysts have weighed in on the stock. Maxim Group reissued a “buy” rating and set a $10.00 price target on shares of Atossa Genetics in a research report on Tuesday. ValuEngine raised shares of Atossa Genetics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Finally, Noble Financial set a $10.00 price target on shares of Atossa Genetics and gave the company a “buy” rating in a research report on Tuesday, May 15th.

Atossa Genetics (NASDAQ:ATOS) last posted its earnings results on Monday, May 14th. The company reported ($0.71) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.86) by $0.15. equities research analysts expect that Atossa Genetics Inc will post -3.72 EPS for the current year.

About Atossa Genetics

Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.

Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply